Statin+Pipeline

Statin+™ is Indication Bioscience’s platform for developing rational fixed-dose combination therapies designed to preserve the established efficacy of statins while improving long-term tolerability and adherence.

The platform integrates a well-characterized small molecule into statin formulations using a repeatable scientific, regulatory, and intellectual-property framework. This approach is intended to address real-world limitations of statin therapy without altering the proven lipid-lowering mechanism that underpins cardiovascular risk reduction.This fixed-dose combination concept is intended to deliver synergistic benefits, including:

• Improved lipid-lowering efficacy
• Reduction in arterial plaque formation
• Mitigation of common statin-associated side effects

Because the Statin+™ framework applies broadly across the statin class, it supports a scalable pipeline of differentiated cardiovascular products that build on decades of established safety and efficacy.

For more information about the Statin+™ platform and ongoing clinical development programs, please contact us.

Statins remain the foundation of lipid-lowering therapy and are among the most widely prescribed medicines worldwide. However, in routine clinical practice, tolerability concerns, perceived adverse effects, and metabolic considerations frequently lead to dose reduction or discontinuation, limiting the long-term effectiveness of therapy.

The Statin+™ platform is designed to address these challenges by optimizing combination formulations that support sustained statin use over time, while maintaining the established safety and efficacy profile of the underlying statin.Statins are the cornerstone of lipid-lowering therapy and among the most widely prescribed medications globally. They have been proven to reduce cardiovascular events and mortality in high-risk individuals. However, statins are also associated with side effects such as muscle pain, liver enzyme elevations, and increased risk of diabetes, which can limit long-term adherence.

The Statin+™ platform is designed to advance statin therapy by pairing statins with a complementary, FDA-approved small molecule. This innovative combination aims to provide a safer, more effective option for both current statin users and those who have discontinued or cannot tolerate standard statin therapy.